rhGAD65 formulated in Alhydrogel® (Diamyd®)

DRUG2 trials

Sponsors

Diamyd Therapeutics AB

Conditions

Latent Autoimmune Diabetes in Adult (LADA)Type 1 Diabetes

Phase 2

Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes

CompletedNCT00435981

Diamyd Therapeutics ABType 1 Diabetes

Start: 2005-01-31End: 2007-12-31Target: 70Updated: 2008-01-30

Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)

CompletedNCT00456027

Diamyd Therapeutics ABLatent Autoimmune Diabetes in Adult (LADA)

Start: 2004-12-31End: 2008-04-30Updated: 2011-06-10

Related Papers

Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD<sub>65</sub>-induced immune response.

2017-03-299 citations

Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.

2010-11-3052 citations

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

2008-10-08344 citations